Analysis of baseline variables for their effect on major cytogenetic response
Factors . | No. subjects . | No. subjects with major cytogenetic response . | Univariate P . | Multivariate P(n = 48) . |
|---|---|---|---|---|
| Sex | ||||
| Male | 37 | 9 | .107 | NA |
| Female | 25 | 11 | ||
| Age | ||||
| Younger than 60 y | 37 | 14 | .256 | NA |
| Older than 60 y | 25 | 6 | ||
| Disease*duration | ||||
| Fewer than 12 mo | 16 | 9 | .024 | NS |
| Longer than 12 mo | 45 | 11 | ||
| Prior therapy*† | ||||
| None, HU, IFN | 35 | 17 | .003 | .037 |
| Others | 27 | 3 | ||
| Prior treatment with 6-thioguanine | ||||
| No | 57 | 20 | .971 | NA |
| Yes | 5 | 0 | ||
| Phase* | ||||
| Chronic | 20 | 13 | <.001 | NS |
| Accelerated + blastic | 42 | 7 | ||
| Clonal evolution* | ||||
| Yes | 24 | 4 | .082 | NA |
| No | 34 | 13 | ||
| Splenomegaly | ||||
| Yes | 43 | 16 | .435 | NA |
| No | 12 | 3 | ||
| Hemoglobin level* | ||||
| More than 100 g/L | 24 | 2 | .005 | NS |
| Less than 100 g/L | 37 | 17 | ||
| White blood cell count* | ||||
| More than 10 × 109/L | 19 | 9 | .095 | NS |
| Fewer than 10 × 109/L | 43 | 11 | ||
| Platelet count | ||||
| 100 × 109/L or fewer | 16 | 5 | >.99 | NA |
| More than 100 × 109/L but less than 450 × 109/L | 28 | 10 | ||
| More than 450 × 109/L | 16 | 5 | ||
| Blasts (PB) | ||||
| 5% or less | 40 | 20 | .940 | NA |
| More than 5% | 20 | 0 | ||
| Basophils (PB) | ||||
| 7% or less | 41 | 14 | .951 | NA |
| More than 7% | 18 | 6 | ||
| Blasts (BM)*‡ | ||||
| 5% or less | 28 | 16 | .001 | .0146 |
| More than 5% | 25 | 3 | ||
| Mutation | ||||
| Yes | 14 | 3 | .330 | NA |
| No | 48 | 17 |
Factors . | No. subjects . | No. subjects with major cytogenetic response . | Univariate P . | Multivariate P(n = 48) . |
|---|---|---|---|---|
| Sex | ||||
| Male | 37 | 9 | .107 | NA |
| Female | 25 | 11 | ||
| Age | ||||
| Younger than 60 y | 37 | 14 | .256 | NA |
| Older than 60 y | 25 | 6 | ||
| Disease*duration | ||||
| Fewer than 12 mo | 16 | 9 | .024 | NS |
| Longer than 12 mo | 45 | 11 | ||
| Prior therapy*† | ||||
| None, HU, IFN | 35 | 17 | .003 | .037 |
| Others | 27 | 3 | ||
| Prior treatment with 6-thioguanine | ||||
| No | 57 | 20 | .971 | NA |
| Yes | 5 | 0 | ||
| Phase* | ||||
| Chronic | 20 | 13 | <.001 | NS |
| Accelerated + blastic | 42 | 7 | ||
| Clonal evolution* | ||||
| Yes | 24 | 4 | .082 | NA |
| No | 34 | 13 | ||
| Splenomegaly | ||||
| Yes | 43 | 16 | .435 | NA |
| No | 12 | 3 | ||
| Hemoglobin level* | ||||
| More than 100 g/L | 24 | 2 | .005 | NS |
| Less than 100 g/L | 37 | 17 | ||
| White blood cell count* | ||||
| More than 10 × 109/L | 19 | 9 | .095 | NS |
| Fewer than 10 × 109/L | 43 | 11 | ||
| Platelet count | ||||
| 100 × 109/L or fewer | 16 | 5 | >.99 | NA |
| More than 100 × 109/L but less than 450 × 109/L | 28 | 10 | ||
| More than 450 × 109/L | 16 | 5 | ||
| Blasts (PB) | ||||
| 5% or less | 40 | 20 | .940 | NA |
| More than 5% | 20 | 0 | ||
| Basophils (PB) | ||||
| 7% or less | 41 | 14 | .951 | NA |
| More than 7% | 18 | 6 | ||
| Blasts (BM)*‡ | ||||
| 5% or less | 28 | 16 | .001 | .0146 |
| More than 5% | 25 | 3 | ||
| Mutation | ||||
| Yes | 14 | 3 | .330 | NA |
| No | 48 | 17 |